# A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

> **NCT02333513** · NA · UNKNOWN · sponsor: **Hebei Yanda Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Recurrent High-grade Glioma

## Interventions

- **DRUG:** Lomustine/Vincristine/Procarbazine

## Key facts

- **NCT ID:** NCT02333513
- **Lead sponsor:** Hebei Yanda Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2015-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02333513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02333513, "A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02333513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*